StockMarketWire.com - Biopharmaceutical company Hutchison China MediTech said it had initiated a phase 3 registration study of its drug to treat patients with metastatic colorectal cancer in the US, Europe and Japan.

The first patient was dosed on 3 September in the US.

Story provided by StockMarketWire.com